METTL3 and hepatocellular carcinoma: Survival analysis of patients showed that METTL3 (a writer) is a prognostic factor for poor outcomes in HCC (Lin et al., 2020), thyroid carcinoma (Wang et al., 2020a), pancreatic cancer (Xia et al., 2019), CRC (Li et al., 2019b), gastric cancer (Wang et al., 2020c), and colorectal cancer (Chen et al., 2021a).